Please check your internet connection and try again.
# L-Ornithine L-Aspartate (Hepamerz)
## Overview
L-Ornithine L-Aspartate (LOLA) is a combination of two amino acids used in the management of hepatic encephalopathy. It is thought to promote ammonia detoxification in the liver and brain.
## Primary Indications
Treatment of hepatic encephalopathy associated with hyperammonemia.
## Adult Dosing
* **Initial Dose:** 10 to 20 mL (containing 5g L-Ornithine and 5g L-Aspartate) diluted in 500 mL of IV fluid (e.g., dextrose 5% in water, saline) infused over 30-60 minutes.
* **Maintenance Dose:** 10 to 20 mL every 8-12 hours, depending on the severity of hepatic encephalopathy and patient response.
* **Maximum Daily Dose:** Typically not to exceed 40 mL per day (20g L-Ornithine and 20g L-Aspartate). Some sources suggest up to 60 mL may be used under close monitoring. Actual maximum dose is dependent on local protocol and clinical judgment.
## Pediatric Dosing
Limited data exists for pediatric use. Dosing should be individualized by a specialist based on age, weight, and clinical status. Consultation with a pediatric intensivist or gastroenterologist is recommended.
## Dose Adjustments
* **Renal Impairment:** No specific dose adjustment guidelines are established due to the primary metabolism in the liver. However, caution is advised in patients with severe renal impairment as ammonia levels might be less responsive or clearance could be affected.
* **Hepatic Impairment:** The drug is intended for patients with hepatic impairment. Dosing is guided by the severity of hepatic encephalopathy and ammonia levels.
## Contraindications
* Known hypersensitivity to L-ornithine, L-aspartate, or any component of the formulation.
* Severe renal failure.
## Adverse Effects
* Nausea and vomiting
* Abdominal pain
* Diarrhea
* Flatulence
* Headache
* Dizziness
* Fatigue
* Skin rash
* Rarely, transient increase in liver enzymes has been reported.
## Key Drug Interactions
No significant drug interactions are well-documented. However, concurrent use of other medications affecting ammonia metabolism or CNS function should be monitored closely.
## Monitoring
* **Clinical Status:** Neurological status, including level of consciousness and cognitive function, should be assessed regularly.
* **Ammonia Levels:** Monitor serum ammonia levels to assess efficacy and guide dosing adjustments.
* **Renal Function:** Monitor renal function (BUN, creatinine) especially in patients with pre-existing renal disease.
* **Liver Function:** Monitor liver function tests periodically.
* **Electrolytes:** Monitor serum electrolytes.
## Clinical Pearls
* LOLA is typically administered intravenously in acute settings of hepatic encephalopathy. Oral formulations may be available for chronic management but are less common.
* The efficacy of LOLA is dependent on adequate liver function to metabolize ammonia.
* Treatment should be part of a comprehensive management plan for hepatic encephalopathy, including addressing the underlying cause and supportive care.
* If the patient does not show clinical improvement or if ammonia levels do not decrease, other treatment strategies should be considered.
***
*Disclaimer: This information is intended for healthcare professionals. Always consult the most current prescribing information and institutional protocols before administering any medication. This response does not substitute for professional clinical judgment.*
